SCHEMBL1574541

SCHEMBL1574541

CCCN(c1ccccc1)C1CN(C(=O)Nc2ccc3ccccc3c2)C1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
UBE2M P61081 1/20 0.45
DCUN1D1 Q96GG9 1/20 0.45
KDM4E B2RXH2 4/20 0.45
TRPV1 Q8NER1 1/20 0.44
RAB9A P51151 3/20 0.44
NPC1 O15118 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
LMNA P02545 1/20 0.44
EPHX2 P34913 1/20 0.43
FAAH O00519 1/20 0.42
MEN1 O00255 3/20 0.41
KMT2A Q03164 3/20 0.41
CYP1A2 P05177 2/20 0.41
ALDH1A1 P00352 1/20 0.41
CYP2C19 P33261 1/20 0.41
HIF1A Q16665 1/20 0.41
EPHX1 P07099 1/20 0.41
MAPT P10636 3/20 0.41
POLB P06746 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1575057 0.91 KDM4E (0.46) UBE2MDCUN1D1KDM4ERAB9ANPC1
SCHEMBL1575336 0.87 HPGD (0.47) KDM4ERAB9ANPC1SMN1; SMN2FAAH
SCHEMBL1574584 0.87 NPC1 (0.53) UBE2MDCUN1D1RAB9ANPC1SMN1; SMN2
SCHEMBL1575334 0.86 KDM4E (0.47) UBE2MDCUN1D1KDM4ERAB9ANPC1
SCHEMBL1574520 0.85 GRIN2B (0.51) UBE2MDCUN1D1RAB9ANPC1SMN1; SMN2
SCHEMBL1574544 0.85 FAAH (0.48) UBE2MDCUN1D1TRPV1RAB9ANPC1
SCHEMBL1575479 0.85 GRIN2B (0.55) UBE2MDCUN1D1RAB9ANPC1SMN1; SMN2
SCHEMBL1574882 0.85 GRIN2B (0.53) UBE2MDCUN1D1RAB9ASMN1; SMN2EPHX2
SCHEMBL1574960 0.84 MAPT (0.49) UBE2MDCUN1D1KDM4ERAB9ANPC1
SCHEMBL1574533 0.84 NPC1 (0.46) UBE2MDCUN1D1RAB9ANPC1FAAH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2308562-A2 Azetidine ring compounds and drugs comprising the same Ono Pharmaceutical Co., Ltd. (JP) 2011-04-13 EP disclosed
US-7511159-B2 Azetidine ring compounds and drugs comprising the same ONO PHARMACEUTICAL CO., LTD. (JP) 2009-03-31 US disclosed
US-20070135402-A1 Azetidine ring compounds and drugs comprising the same ONO PHARMACEUTICAL CO., LTD. (JP) 2007-06-14 US disclosed
EP-1698375-A1 AZETIDINE RING COMPOUNDS AND DRUGS COMPRISING THE SAME ONO PHARMACEUTICAL CO., LTD. (JP) 2006-09-06 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070135402-A1 Azetidine ring compounds and drugs comprising the same EDNRA, LIPG, EDNRB UBE2M 3832/4885DCUN1D1 3316/4885KDM4E 516/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.